Published 10 August 2009, doi:10.1136/bmj.b3172
Cite this as: BMJ 2009;339:b3172

Research

Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

¹ Kadoorie Centre, John Radcliffe Hospital, Headington, Oxford OX3 9DU, ² Oxford University Department of Primary Health Care, Rosemary Rue Building, Headington, Oxford OX3 7LF

Objective To assess the effects of the neuraminidase inhibitors oseltamivir and zanamivir in treatment of children with seasonal influenza and prevention of transmission to children in households.

Design Systematic review and meta-analysis of data from published and unpublished randomised controlled trials.

Data sources Medline and Embase to June 2009, trial registries, and manufacturers and authors of relevant studies.

Review methods Eligible studies were randomised controlled trials of neuraminidase inhibitors in children aged 12 in the community (that is, not admitted to hospital) with confirmed or clinically suspected influenza. Primary outcome measures were time to resolution of illness and incidence of influenza in children living in households with index cases of influenza.

Results We identified four randomised trials of treatment of influenza (two with oseltamivir, two with zanamivir) involving 1766 children (1243 with confirmed influenza, of whom 55-69% had influenza A), and three randomised trials for postexposure prophylaxis (one with oseltamivir, two with zanamivir) involving 863 children; none of these trials tested efficacy with the current pandemic strain. Treatment trials showed reductions in median time to resolution of symptoms or return to normal activities, or both, of 0.5-1.5 days, which were significant in only two trials. A 10 day course of postexposure prophylaxis with zanamivir or oseltamivir resulted in an 8% (95% confidence interval 5% to 12%) decrease in the incidence of symptomatic influenza. Based on only one trial, oseltamivir did not reduce asthma exacerbations or improve peak flow in children with asthma. Treatment was not associated with reduction in overall use of antibiotics (risk difference –0.30, –0.13 to 0.01). Zanamivir was well tolerated, but oseltamivir was associated with an increased risk of vomiting (0.05, 0.02 to 0.09, number needed to harm=20).

Conclusions Neuraminidase inhibitors provide a small benefit by shortening the duration of illness in children with seasonal influenza and reducing household transmission. They have little effect on asthma exacerbations or the use of antibiotics. Their effects on the incidence of serious complications, and on the current A/H1N1 influenza strain remain to be determined.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Antiviral drugs: distinguish treatment from prophylaxis

Benjamin J Cowling, Sophia Ng, and Ira M Longini, Jr
BMJ 2009 339: b3620. [Extract] [Full Text]

Pandemic flu: will there be a second wave?

Fiona Godlee
BMJ 2009 339: b3394. [Extract] [Full Text]

Bringing some breathing space to the NHS

Nigel Hawkes
BMJ 2009 339: b3358. [Extract] [Full Text]

Oseltamivir’s adverse events

Mark Strong, Julia Burrows, and Paul Redgrave
BMJ 2009 339: b3249. [Extract] [Full Text]

Measuring inconsistency in meta-analyses

Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, and Douglas G Altman
BMJ 2003 327: 557-560. [Extract] [Full Text] [PDF]

Related external webpages:

Read Carl Heneghan and Matthew Thompson's blog about the media coverage of this paper

Carl Henegan and Matthew Thompson talk about the media response to their research in the BMJ podcast

This article has been cited by other articles:

• Cowling, B. J, Ng, S., Longini, I. M Jr (2009). Antiviral drugs: distinguish treatment from prophylaxis. BMJ 339: b3620-b3620 [Full text]  
• (2009). Antivirals Slightly Shorten Duration of Seasonal Flu in Children. JWatch Emergency Med. 2009: 2-2 [Full text]  
• (2009). What's New with the Flu?. JWatch Pediatrics 2009: 1-1 [Full text]  

Rapid Responses:

Read all Rapid Responses

Media

Bastiaan Kole
bmj.com, 11 Aug 2009 [Full text]

Effectiveness of antivirals: Important to distinguish treatment from prophylaxis

Benjamin J. Cowling, et al.
bmj.com, 11 Aug 2009 [Full text]

Antiviral drugs for treating influenza: Effectiveness in children similar to that for at-risk and otherwise healthy adults

Jane Burch, et al.
bmj.com, 12 Aug 2009 [Full text]

Neuraminidase inhibitors: Are they cost-effective?

Rajiv Mahajan, et al.
bmj.com, 14 Aug 2009 [Full text]

Children with novel H1N1 Warrant Treatment

Richard Whitley
bmj.com, 17 Aug 2009 [Full text]

Experiences of the flu

Sherine Thomas, et al.
bmj.com, 18 Aug 2009 [Full text]

Disease mongering by WHO

Juan Gérvas
bmj.com, 22 Aug 2009 [Full text]

We need a randomised trial of antiviral therapy for pandemic flu

B Ronan O'Driscoll, et al.
bmj.com, 26 Aug 2009 [Full text]

Parental anxiety over oseltamivir

Kelsey DJ Jones, et al.
bmj.com, 19 Oct 2009 [Full text]

Oseltamivir for children with suspected influenza A H1N1

Marta Gómez Fernández-Vegue, et al.
bmj.com, 29 Oct 2009 [Full text]

Online poll

Find out more on doc2doc >>